Additionally, RT sensitizes tumor cells to immune-cell-mediated killing by upregulating MHC-1 expression and inducing the release of pro-inflammatory cytokines via a type 1 interferon (IFN) response, which further stimulates CD8+ T cells (7, 32–36). Here, CD8A is linked to neoplasm.